Continuous metronomic temozolamide with propranolol and etodolac in recurrent globlastoma: A pilot study.

e13005 Background: Glioblastoma is a extremely difficult disease to treat and recurrences are extremely high. Salvage treatment is of limited value. This remains an unmet need in oncology. Methods: Since 2003 to 2012, 32 patients of recurrent glioblastoma, post radiotherapy (concomitant with Temozolamide, followed by adjuvant Temozolamide) were taken. 32 patients were above the age of 65years and of the 32 in 9 patients it was partially resected. Patients were randomized to 2 groups, Arm A - with metronomic therapy with temozolamide and Arm B - of metronomic temozolamide combined with propranolol (eccentric dosing) and etodolac, (VT-122). Propranolol was titrated to maintain heart rate around 80 per minute. The primary end point was progression free survival at 6 months. Patients were assessed by MRI using Mac Donalds criteria. DWI criteria for vascularization was used. Results: The median time to progression was 5.2 months in Arm A and in Arm B it was 8.8 months. 6 months survival was 40% and 63% respect...